This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,119,113.00 to the University of Illinois to explore metabolic vulnerabilities in KRAS G12C inhibitor resistance. The funding will support a 2-year research project from July 1, 2023 to June 30, 2025, investigating new approaches to overcoming drug resistance in cancer treatment. As a major research university, the University of Illinois has extensive experience conducting biomedical research under federal grants and contracts. The university's collaboration on this project aims to transform healthcare for service members and the American public through innovative cancer research.
Generated 6/25/24, 6:39 AM